87 related articles for article (PubMed ID: 3751378)
1. [Autoradiographic determination of 3H-thymidine incorporation in ovarian tumor cells and the value of this in vitro study for tumor chemotherapy].
Behling H; Krafft W; Wagner F
Zentralbl Gynakol; 1986; 108(11):684-90. PubMed ID: 3751378
[TBL] [Abstract][Full Text] [Related]
2. [Scintillation counting as an in vitro method for assessing the pretherapeutic effectiveness of planned tumor chemotherapy in patients with ovarian cancer].
Behling H; Krafft W; Wagner F
Zentralbl Gynakol; 1987; 109(1):42-8. PubMed ID: 3577462
[TBL] [Abstract][Full Text] [Related]
3. The behaviour of tumour cells of ovarian carcinomata under in vitro conditions and the coincidence with clinical controllability of tumours.
Krafft W; Brückmann D; Brückmann J; Preibsch W; Behling H; Kademann J
Arch Geschwulstforsch; 1981; 51(1):133-8. PubMed ID: 7259435
[TBL] [Abstract][Full Text] [Related]
4. Comparative autoradiographic in vitro study of the incorporation of 3H-thymidine and 3H-uridine into the DNA and RNA of solid tumours in children.
Willnow U
Arch Geschwulstforsch; 1980; 50(8):778-84. PubMed ID: 7224820
[TBL] [Abstract][Full Text] [Related]
5. Cost-effective treatment of women with advanced ovarian cancer by cytoreductive surgery and chemotherapy directed by an in vitro assay for drug resistance.
Orr JW; Orr P; Kern DH
Cancer J Sci Am; 1999; 5(3):174-8. PubMed ID: 10367175
[TBL] [Abstract][Full Text] [Related]
6. In vitro drug testing of ovarian cancer using the human tumor colony-forming assay: comparison of in vitro response and clinical outcome.
Federico M; Alberts DS; Garcia DJ; Emerson J; Fanta P; Liu R; Salmon SE
Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S156-63. PubMed ID: 7835801
[TBL] [Abstract][Full Text] [Related]
7. Clinical correlations with chemosensitivities measured in a rapid thymidine incorporation assay.
Sondak VK; Bertelsen CA; Tanigawa N; Hildebrand-Zanki SU; Morton DL; Korn EL; Kern DH
Cancer Res; 1984 Apr; 44(4):1725-8. PubMed ID: 6704978
[TBL] [Abstract][Full Text] [Related]
8. The clinical predictivity of biomarkers of stage III-IV epithelial ovarian cancer in a prospective randomized treatment protocol.
Silvestrini R; Daidone MG; Veneroni S; Benini E; Scarfone G; Zanaboni F; Villa A; Presti M; Danese S; Bolis G
Cancer; 1998 Jan; 82(1):159-67. PubMed ID: 9428493
[TBL] [Abstract][Full Text] [Related]
9. [Recurrent and 2nd line therapy in ovarian carcinoma: an overview of conventional systemic therapy modalities].
du Bois A; Lück HJ; Meerpohl HG
Zentralbl Gynakol; 1997; 119(7):299-323. PubMed ID: 9340970
[TBL] [Abstract][Full Text] [Related]
10. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells.
Pietras RJ; Fendly BM; Chazin VR; Pegram MD; Howell SB; Slamon DJ
Oncogene; 1994 Jul; 9(7):1829-38. PubMed ID: 7911565
[TBL] [Abstract][Full Text] [Related]
11. [Pretherapeutic chemosensitivity testing of ovarian cancer and possibilities for its clinical use].
Hernádi Z; Pásti G; Lampé L; Juhász B
Zentralbl Gynakol; 1985; 107(17):1065-71. PubMed ID: 4060913
[TBL] [Abstract][Full Text] [Related]
12. Inhibitory effect of bombesin receptor antagonist RC-3095 on the growth of human pancreatic cancer cells in vivo and in vitro.
Qin Y; Ertl T; Cai RZ; Halmos G; Schally AV
Cancer Res; 1994 Feb; 54(4):1035-41. PubMed ID: 8313359
[TBL] [Abstract][Full Text] [Related]
13. Effects of hydroxyurea on extrachromosomal DNA in patients with advanced ovarian carcinomas.
Raymond E; Faivre S; Weiss G; McGill J; Davidson K; Izbicka E; Kuhn JG; Allred C; Clark GM; Von Hoff DD
Clin Cancer Res; 2001 May; 7(5):1171-80. PubMed ID: 11350881
[TBL] [Abstract][Full Text] [Related]
14. Adenovirus mediated thymidine kinase gene therapy may enhance sensitivity of ovarian cancer cells to chemotherapeutic agents.
Tong X; Shine DH; Agoulnik I; Freund CT; Hasenburg A; Aguilar-Cordova E; Woo SL; Kieback DG
Anticancer Res; 1998; 18(5A):3421-6. PubMed ID: 9858918
[TBL] [Abstract][Full Text] [Related]
15. [Correlation between ATP bioluminescence tumor chemosensitivity assay and clinical response in ovarian cancer].
Tian HM; Shi XY; Fu J; Chao DY; Zhang K; Wu LY; Wang JW; Zhang W
Zhonghua Zhong Liu Za Zhi; 2005 May; 27(5):296-8. PubMed ID: 15996325
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of cell proliferation and cell death based assays in chemosensitivity testing.
Gerçel-Taylor C; Ackermann MA; Taylor DD
Anticancer Res; 2001; 21(4A):2761-8. PubMed ID: 11724352
[TBL] [Abstract][Full Text] [Related]
17. In vitro DNA synthesis in freshly separated human breast cancer cells assessed by tritiated thymidine incorporation assay: relationship to the long-term outcome of patients.
Nio Y; Tamura K; Kan N; Inamoto T; Ohgaki K; Kodama H
Br J Surg; 1999 Nov; 86(11):1463-9. PubMed ID: 10583297
[TBL] [Abstract][Full Text] [Related]
18. Gynecological malignancies.
Schaebler DL; Schilder RJ; Young RC
Cancer Chemother Biol Response Modif; 1996; 16():564-91. PubMed ID: 8639401
[TBL] [Abstract][Full Text] [Related]
19. Evidence for a dose-response effect between p53 (but not p21WAF1/Cip1) protein concentrations, survival, and responsiveness in patients with epithelial ovarian cancer treated with platinum-based chemotherapy.
Levesque MA; Katsaros D; Massobrio M; Genta F; Yu H; Richiardi G; Fracchioli S; Durando A; Arisio R; Diamandis EP
Clin Cancer Res; 2000 Aug; 6(8):3260-70. PubMed ID: 10955812
[TBL] [Abstract][Full Text] [Related]
20. Serum tumour marker CA 125 in monitoring of ovarian cancer during first-line chemotherapy.
Tuxen MK; Sölétormos G; Dombernowsky P
Br J Cancer; 2001 May; 84(10):1301-7. PubMed ID: 11355938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
